Third-Party Social Media Sites: Firms Should Not Be Selective In Corrections
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s draft guidance on correcting independent third-party misinformation about Rx drugs and devices advises firms to address exaggerated efficacy claims as well as incorrect risk information.